HLS Therapeutics Inc News - HLS

HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust

HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust Canada NewsWire TORONTO, July 2, 2024 Total...

HLS Therapeutics Reports Annual Meeting Results

HLS Therapeutics Reports Annual Meeting Results Canada NewsWire TORONTO, June 7, 2024 TORONTO, June 7, 2024 /CNW/ - HLS Therapeutics Inc...

New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment

New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment Canada NewsWire DORVAL, QC, May 28...

HLS Therapeutics Announces Q1 2024 Financial Results

HLS Therapeutics Announces Q1 2024 Financial Results Canada NewsWire TORONTO, May 9, 2024 TORONTO, May 9, 2024 /CNW/ - HLS Therapeutics Inc...

HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call

HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call Canada NewsWire TORONTO, April 25, 2024 TORONTO, April 25, 2024 /CNW/...

HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference Canada NewsWire TORONTO, April 9, 2024 TORONTO...

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups Canada...

HLS Therapeutics Announces Fiscal 2023 Financial Results

HLS Therapeutics Announces Fiscal 2023 Financial Results Canada NewsWire TORONTO, March 14, 2024 TORONTO, March 14, 2024 /CNW/ - HLS Therapeutics...

HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call

HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call Canada NewsWire TORONTO, Feb. 29, 2024 TORONTO, Feb. 29, 2024 /CNW/...

HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan

HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan Canada NewsWire TORONTO, Feb. 6, 2024 Public...

HLS Therapeutics Announces CFO Departure

HLS Therapeutics Announces CFO Departure Canada NewsWire TORONTO, Dec. 18, 2023 John Hanna appointed Interim CFO to replace departing CFO Tim...

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in...

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid Canada NewsWire TORONTO, Nov. 9, 2023...

HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call

HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call Canada NewsWire TORONTO, Oct. 26, 2023 TORONTO, Oct. 26, 2023 /CNW/...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

HLS Therapeutics Inc (HLS)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

HLS News

HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust

HLS Therapeutics Reports Annual Meeting Results

New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment

HLS Therapeutics Announces Q1 2024 Financial Results

HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call

HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

HLS Therapeutics Announces Fiscal 2023 Financial Results

HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call

HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan

HLS Therapeutics Announces CFO Departure

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call

HLS Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

HLS Therapeutics Inc (HLS) News

HLS Therapeutics Inc (HLS)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

HLS News

HLS Therapeutics Announces the Sale of its XENPOZYME® Royalty Interest to DRI Healthcare Trust

HLS Therapeutics Reports Annual Meeting Results

New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment

HLS Therapeutics Announces Q1 2024 Financial Results

HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call

HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

HLS Therapeutics Announces Fiscal 2023 Financial Results

HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call

HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan

HLS Therapeutics Announces CFO Departure

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call

HLS Discussion

Your Recent History